Specify a stock or a cryptocurrency in the search bar to get a summary
Ocean Biomedical Inc.
OCEAOcean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP. The company is based in Providence, Rhode Island. Ocean Biomedical, Inc. operates as a subsidiary of Poseidon Bio, LLC. Address: Room 325, 55 Claverick Street, Providence, RI, United States, 02903
Analytics
WallStreet Target Price
18.5 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures OCEA
Dividend Analytics OCEA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History OCEA
Stock Valuation OCEA
Financials OCEA
Results | 2019 | Dynamics |